gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE American · ARMPHealthcareBiotechnology

Armata Pharmaceuticals, Inc. Common Stock (ARMP)

$3.14+1.62%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$3.14▼ 35.12% in range
Nov 4, 2025Low $2.78 · High $14.80Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Armata Pharmaceuticals closed at $3.14 on Nov 4, up 1.62%, 78.8% below its 52-week closing high. Volume of 64.2K shares was 0.66× its 20-day average (below normal).

Split-adjusted performance: -18.4% over one month, -65.3% over six months, -35.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $2.51M, up 15.7% from a year earlier, with a net margin of 2953.8%.

Short interest was 899.6K shares at the Oct 15 settlement, down 6.7% from the prior report (4.4% of float, 8.5 days to cover).

Market cap$116.8M37.2M shares
Revenue · quarter$2.5M+15.7% YoY
Diluted EPS$-0.27—
P/E · TTM—P/S 21.1×
Net margin2,953.8%Gross 100.0%
Dividend yieldNone
52-week range2.78 – 14.80−78.8% from high
Volume64.2K0.66× 20-day avg
Volatility · 60d114.9%Annualised
Short % of float4.4%8.5 days to cover
Net cash-$259.6MCash $24.0M
Next earnings—Not scheduled
Split-adjusted performance
1W −4.6%1M −18.4%3M −33.2%6M −65.3%YTD −50.0%1Y −35.0%3Y +38.3%5Y +6.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum14
Revenue growth60
Net margin100
Value (low P/E)—
Size38

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short899.6K−6.7% vs prior
Days to cover8.5Settled Oct 15
% of float4.4%
Short vol. 10d65.3%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ARMPArmata Pharmaceuticals$3.14+1.62%−65.3%+15.7%2953.8%—$116.8M
AVXLAnavex Life Sciences$1.26+5.00%−62.3%———$116.8MCompare
ENGNenGene Therapeutics$1.72+6.17%−80.6%———$115.3MCompare
VYGRVoyager Therapeutics$1.87+2.19%−55.2%−39.1%−773.2%—$115.2MCompare
OTLKOutlook Therapeutics$0.4621+0.46%+99.4%−99.4%−233554.9%—$112.5MCompare
BDTXBlack Diamond Therapeutics$1.90+4.97%−32.6%———$109.2MCompare
HUMAHumacyte$0.4500+2.16%−54.2%+34.9%−9064.5%—$125.0MCompare
LENZLENZ Therapeutics$3.46−1.14%−64.3%+9.7%−581.8%—$108.7MCompare
NMRANeumora Therapeutics$0.5660−0.86%−75.7%———$106.3MCompare

News about Armata Pharmaceuticals

All news →

No recent articles focused on Armata Pharmaceuticals. 2 articles mention it in passing.

Quick answers

What does Armata Pharmaceuticals do?
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date.
What is ARMP's market cap?
$116.75M, based on the Nov 4 close of $3.14.
Does Armata Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ARMP is sold short?
899.6K shares, 4.4% of float, as of Oct 15, 2026.
What sector is ARMP in?
Healthcare, in the Biotechnology industry.

About Armata Pharmaceuticals

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

HQ: Los Angeles, CA61 employeesListed May 27, 1994armatapharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology